Study Suggests Well-Known Growth Suppressor Actually Fuels Lethal Brain Cancers
Research Points to Potential Treatment Target That Lacks a Workable Drug
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it from being advanced for testing as a therapeutic strategy for patients with few treatment options.
Researchers at the Cincinnati Children’s Cancer and Blood Diseases Institute point to a protein that helps regulate cell metabolism called AMPK (AMP-activated protein kinase). Their data suggest AMPK is a key driver of the mostly untreatable brain cancers, and blocking it may produce therapeutic benefit for very ill patients.
But the finding also challenges the scientific status quo regarding AMPK. This is because current research literature characterizes it as a cancer suppressor, according to the study’s senior investigators, Biplab Dasgupta, PhD, and first author Rishi Raj Chhipa, PhD—both scientists in the Division of Oncology at Cincinnati Children’s.
Click here to read more.
14th International Conference on Neurology, Neuroscience and Neuromuscular Disorders
June 17-18, 2019; Tokyo
CARS 2019 Computer Assisted Radiology and Surgery
June 18-21, 2019; Rennes, France
18th Meeting of WSSFN
June 24-27, 2019; New York
International Summer School Transnasal Endoscopic Surgery: From Sinuses to Skull Base
June 24-28, 2019; Brescia, Italy
The Society of University Neurosurgeons Annual Meeting
June 26-30, 2019; Dubrovnik, Croatia